A new FDA clearance for in-stent restenosis | Patient frailty & AVR outcomes | PCI vs. CABG for left main CAD

The solution is now cleared as a treatment option for in-stent restenosis in the lower extremity arteries.

Frailty measurements may still provide helpful information in other ways, of course. 

Researchers examined data from the SYNTAX, PRECOMBAT, NOBLE and EXCEL trials, sharing their findings in The Lancet.

The blood-based biomarker was previously associated with worse acute coronary syndrome outcomes. What does it mean for TAVR patients?

Researchers said they hope their findings can shine new light on this "complex relationship."

“Cell therapy has the potential to change how we treat heart failure,” one researcher said.

The company reported that its deep neural network led to improved sensitivity and fewer unclassified findings. 

The two-part document was published in full in European Heart Journal. 

The cardiologist's message has been spread throughout Malaysia and other parts of the world.

The analysis, presented at AHA Scientific Sessions 2021, included approximately 2,000 symptomatic COVID-19 patients who were not necessarily sick enough to be hospitalized. 

An initial analysis revealed Paxlovid reduced the risk of hospitalization or death in high-risk patients who took the pill within 3 days of experiencing symptoms.